Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) MeetingPRNewsWire · 2 days ago
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 8, 2026
Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 11, 2026
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire · Aug 11, 2026
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026PRNewsWire · Aug 4, 2026Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.87 | -$1.11 | Miss |
| May 7, 2026 | -$1.19 | -$0.96 | Beat |
| Mar 27, 2026 | -$1.24 | -$1.69 | Miss |
| Nov 6, 2025 | -$1.58 | -$1.50 | Beat |
| Aug 7, 2025 | -$0.30 | -$3.25 | Miss |
| May 13, 2025 | -$5.00 | -$5.50 | Miss |